FDA Approves FENOFIBRATE — Mylan Pharmaceuticals Inc.

On June 23, Mylan Pharmaceuticals Inc. was granted FDA approval for the Abbreviated New Drug Application #ANDA204475 for tablet and capsule forms of Fenofibrate Oral. This approval enables the production of generic versions of the brand-name drug, driving anticipated competition that is expected to impact the lipid-lowering market by lowering prices and increasing patient access to affordable medication.